국소 진행성 절제 불가능 NSCLC 환자를 위한 오시머티닙 FDA 승인
FDA가 국소 진행성 절제 불가능 NSCLC 환자를 위한 오시머티닙 사용을 승인했다.
局所進行性切除不能NSCLCに対するオシメルチニブの承認
FDAは、局所進行性切除不能NSCLC患者に対するオシメルチニブの使用を承認した。
FDA Approves Osimertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, for Unresectable Non-Small Cell Lung Cancer
The FDA has approved the use of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, for the treatment of locally advanced, unresectable non-small cell lung cancer in certain adult patients.
유방암 치료 비용과 생존율 간의 연관성 없음
유방암 치료 비용은 환자의 생존율이나 질병 악화와 관련이 없다.
胃食道がんの新しいバイオマーカーと治療法
胃食道がんの治療において、PD-L1発現状況やCLDN18.2などの新しいバイオマーカーを活用し、FLOT療法やFOLFIRINOX療法などの新しい化学療法レジメンを組み合わせることで、より効果的な治療アプローチが期待できる。
Analysis of Breast Cancer Drug Prices and Their Correlation with Survival and Clinical Benefit
The monthly cost of treating breast cancer is not associated with improved overall survival or progression-free survival for patients.
Emerging Biomarkers and Targeted Therapies for Esophageal and Gastric Cancers: Insights from Leading Oncologists
Oncologists are exploring new biomarker-driven approaches, combination therapies, and sequencing strategies to improve outcomes for patients with esophageal and gastric cancers.
Immunotherapy Transforming Treatment of Advanced Endometrial Cancer: Insights from Leading Expert
Immunotherapy combined with chemotherapy has significantly improved outcomes for patients with advanced or recurrent endometrial cancer, offering substantial survival benefits across different molecular subtypes.
Racial Disparities in Breast Cancer Survival Across Tumor Subtypes in the United States
Black women in the United States have higher breast cancer mortality rates than White women across all tumor subtypes, with the greatest disparity observed in hormone receptor-positive (HR+), human epidermal growth factor 2–negative (HER2−) tumors.
난치성 난소암 치료에 부상하는 새로운 희망: 접합 항체
접합 항체는 난소암 치료에 있어 중요한 새로운 치료법으로 부상하고 있다. 이러한 분자는 암세포를 직접 표적화하여 세포독성 치료제를 전달함으로써 치료 효과를 높이고 부작용을 줄일 수 있다.
© 2024 by Linnk AI